"Amoy Diagnostics Co., Ltd...announces that its AmoyDx® FGFR2 Break-apart FISH Probe Kit has been approved as a companion diagnostic (CDx) for Eisai’s innovative targeted therapy, Tasurgratinib in Japan. This approval marks a significant milestone in precision oncology, enhancing the treatment options for biliary tract cancer patients with FGFR2 gene fusions."